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Abstract 
The opioid epidemic has led to a chain reaction of public health concerns, including an increase 
in heroin usage, injection drug abuse, incidence of hepatitis C virus (HCV), and HIV 
transmission. There have been few population-based studies investigating the clinical and socio-
demographic data associated with opioid use in Nevada (Feng et al., 2016; Frank, 2000) and few 
studies investigating the intravenous drug user (IDU) population in Clark County. On February 
2017, Clark County’s first syringe exchange program (SEP) opened its doors to the IDU 
population. This study provides an updated analysis of opioid-related injuries within Nevada and 
provides a first-time analysis of the IDU population within Clark County. According to the 2017 
Center of Health Information Analysis (CHIA), there were 9,064 opioid-related injuries in the 
state of Nevada. The most common comorbidities associated with opioid-related injuries were 
chronic bodily pains (50.2%), malnutrition (47.3%), nicotine dependence (44.7%), affective 
disorders (32.4%), and hypertension (28.8%). There was a higher proportion of 18-35 year olds 
who used SEPs as compared to 18-35 year olds who used hospitals. One Clark County zip code 
had both high frequencies for opioid-related hospitalizations and injection drug use. In order to 
implement interventions and programs to battle the opioid epidemic and the consequent public 
health effects, we must first understand the associations between opioid-related hospitalizations 
and the IDU population. 
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Introduction 
The U.S. Secretary of the Department of Health and Human Services (HHS) declared the 
current opioid epidemic a public health emergency (Department of Health and Human Services 
[HHS], 2017a). In 2016, more than 11 million people abused prescription opioids (synthetic pain 
relievers) (CDC, 2018b) and approximately 116 people die each day from an opioid-related drug 
overdose (HHS, 2017b). Prescription opioids such as oxycodone, hydrocodone, and methadone 
reportedly caused four times more deaths in 2016 compared to 1999 (CDC, 2018c); this does not 
reflect the use of illicit opioids like heroin. These increases in opioid abuse and death are related 
to several public health concerns derived from the opioid epidemic.   
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Background and Significance 
Public Health Concern – Increase of Heroin Usage 
The opioid epidemic has led to a chain reaction of public health concerns, costing the 
U.S. 56 million dollars in annual societal costs (Rossiter et al., 2014). One of the concerns has 
been the increased number of new heroin users (CDC, 2018a). Among new heroin users, 75% 
reported the use of prescription opioids before trying heroin (CDC, 2018a). It is common for 
prescription opioid users to advance to heroin use (Cicero et al., 2014; Lankenau et al., 2012; 
Mars et al., 2014; Peavy et al., 2012) because of its accessibility, affordability, pain relieving, 
and euphoric affects (Cicero et al., 2012; Cicero et al., 2014; Lankenau et al., 2012; Library of 
Congress, 2014; Mars et al., 2014). In 2016, HHS reported 170,000 people used heroin for the 
first time and 948,000 people were currently using heroin. In addition, there were 15,469 deaths 
attributed to overdosing on heroin alone (HHS, 2017b).   
Public Health Concern – Increase of Injection Drug Abuse 
The number of IDUs have increased consequential to the abuse of opioids and heroin. 
IDUs report that injection of heroin is easier as opposed to the complex break down and 
extraction of prescription opioids (Cicero et al., 2014). Injection of drugs, as opposed to 
ingestion or inhalation, is the most dangerous route of drug administration. It may lead to 
injection-related endocarditis, increased risk for overdose, emergency department visits, 
mortality, and infectious disease transmission (Black et al., 2013; Havens et al., 2007). 
According to Jones, Christensen and Gladden (2017) injection drug abuse increased from 11.7% 
to 18.1% between 2004 and 2013. As injection drug abuse increases, we can expect the number 
of IDUs who do not inject safely (i.e. the reusing and sharing of syringes and injection 
equipment) to increase simultaneously (CDC, 2018d; Strenski, 2000).  
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Public Health Concern – Increase of HIV/ HCV Transmission 
There are many injuries associated with injection drug use; however, the transmission of 
blood-borne viruses, such as HIV and HCV, can have catastrophic results. From 2011 to 2015, 
new HCV infections had doubled and approximately 6% of new HIV diagnoses were attributed 
to injection drug use (CDC, 2018d). According to the CDC (1998), injection drug use was the 
second leading cause of HIV infection (Marx et al., 2001) and continues to be one of the top 
methods of HIV transmission within the U.S. (CDC, 2018d). This is attributed to the reuse and 
sharing of injection equipment (Strenski, 2000). Sterile syringes are meant to be used one time 
and then disposed of; however, obtaining sterile syringes and injection equipment may be 
difficult for IDUs (Aldrich, 1993). 
Syringe Exchange Programs and Public Health Benefits 
One of the proposed solutions to address these public health concerns are SEPs. SEPs 
offer sterile injection equipment and social services without judgement and free of charge. 
During the wake of the HIV pandemic in the 1980’s, distributing sterile syringes to IDUs was 
controversial because a prescription was required (Aldrich, 1993). Anyone caught distributing 
sterile syringes including public health professionals were arrested because authorities believed 
they were enabling the use of illicit drugs (Aldrich, 1993). Today, IDUs may attempt to purchase 
sterile syringes, but may be denied their purchase due to their appearance (Trac-B client, 
personal communication, September 2017). Many IDUs report living in a low-SES area or are 
homeless, therefore it is difficult for them to maintain their hygiene and appearances (Trac-B 
client, personal communication, September 2017). Although a prescription is no longer required 
to purchase syringes, access to sterile syringes continues to be problematic for IDUs resulting in 
the reuse and sharing of injection equipment (Strenski, 2000). 
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One of the consequences of sharing syringes is that HIV can survive in a syringe up to 42 
days depending on temperature and other factors (CDC, 2018d). One study found that a single 
syringe is used an average of 10.7 times by an IDU (Rich, Strong, Towe, & Mckenzie, 1999), 
making their risk for HIV/HCV infection considerably high. Studies have shown SEPs may 
decrease rates of HIV drug risk behavior and may prevent HIV/HCV transmission (Aldrich, 
1993). In addition, SEPs are cost-effective, costing less than $100,000 as compared to the 
lifetime cost of treating one HIV-infected individual, which may be as high as $379,668 
(Aldrich, 1993; CDC, 2017a).  
Nevada & the Opioid Epidemic 
Not all states within the U.S. are affected by the opioid epidemic equally. Currently, 2.9 
million people reside in the state of Nevada and 75% of Nevada residents (2.5 million people) 
live in Clark County (Southern Nevada) (U.S. Census Bureau, 2018a). According to Nevada’s 
Prescription Drug Monitoring Program (PDMP), approximately 2.5 million opioid prescriptions 
were administered in 2016 (Nevada Division of Public and Behavioral Health, 2017). This is 
equivalent to having one opioid prescription for each adult and child who reside in Clark County. 
Nevada has one of the highest rates for opioid prescriptions per capita (CDC, 2017b) and 
Nevada was one of the top five states for HIV diagnoses rates among adults and adolescents in 
2016 (CDC, 2018d). HIV outbreaks are recurring; the most recent HIV outbreak included 11 
cases involving injection drug abuse (CDC, 2018d). With the current prescription rate in Nevada 
and the number of heroin and injection drug users on the rise, an HIV or HCV outbreak may be 
inevitable without intervention.  
Trac-B-Exchange 
As of February 2017, Trac-B-Exchange (Trac-B) became Clark County’s first SEP. Trac-
B is also the first SEP in the U.S. to distribute syringe kits through vending machines. Trac-B 
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distributes sterile needles, injection equipment (i.e. tourniquets, water, cookers, etc.), safe sex 
kits, Naloxone kits (overdose reversal drug), and offers various services. These services include 
HIV/HCV testing, referrals to treatment facilities, safe injection education, how to administer 
Naloxone appropriately, and promote used syringe disposal. There are currently three vending 
machine locations in Clark County as well as the storefront location. These vending machines 
increase access of sterile equipment, supply a greater number of IDUs, and provide a safe place 
to dispose of used syringes. In addition, before the distribution of any equipment or services are 
given to an IDU, the completion of specific forms is mandatory. This provides valuable 
information about a poorly understood population within Southern Nevada. 
Previous Investigations in Nevada 
There have been few population-based studies investigating the clinical and socio-
demographic data associated to opioid use (Feng et al., 2016; Frank, 2000)”, particularly in 
Nevada. One recent Nevada study was conducted by Feng et al. (2016) in Clark County. They 
retrieved CHIA data from 2011 to 2013 and analyzed opioid-related injuries under ICD-9-CM 
codes. Since October 2015, ICD-10-CM codes have been gradually implemented into healthcare 
settings and have increased opioid-related diagnoses from 20 to 100 codes (Moore, 2017). Since 
this change, it was reported that opioid-related hospitalizations had increased 18.3% within the 
first quarter of ICD-10-CM implementation (Moore, 2017). The modification to ICD-10-CM 
codes has increased the number of inpatient (IP) visits and increased the overall cost of opioid-
related hospitalizations, therefore adding to the cost burden of the opioid epidemic. The data 
presented on Nevada’s Opioid Dashboard (2016), presents emergency department and IP 
admissions only and does not account for those who use illicit opioids. Since the opening of 
Clark County’s first SEP, we now have the tools necessary to research a poorly understood 
population within Southern Nevada. 
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Research Questions 
Given the lack of clinical and socio-demographic population-based studies associated 
with opioid use in Nevada (Feng et al., 2016; Frank, 2000); this study supplements current 
knowledge and provides an updated analysis of opioid-related injuries from a clinical 
perspective. In addition, there have been no recent investigations to our knowledge on the socio-
demographic subgroups and injection drug practices of IDUs within Clark County; therefore, this 
study expands our knowledge on a poorly understood population. The following questions were 
investigated: What are the frequent comorbidities and costs associated with opioid-related 
inpatient hospital stays in Nevada? What are the socio-demographic subgroups and drug 
injection patterns of intravenous drug users within Clark County? Is there a difference in 
socioeconomic status (SES) between those who are hospitalized for opioid-related injuries 
compared to IDUs who use Trac-B?  
Hypotheses 
My study provides an updated analysis of opioid-related hospitalizations within the state 
of Nevada, and provides a first-time analysis of the IDU population within Clark County using 
data from a local SEP. By analyzing 2017 CHIA data, the correlation between the total number 
of comorbidities associated with opioid-related injuries and cost was determined. The socio-
demographic subgroups for both CHIA and Trac-B data; and the drug injection practices of the 
IDU population within Clark County was analyzed. Lastly, the geographical patterns among 
those who use hospitals and those who use SEPs was determined.  
Objective 1 
To determine the frequent comorbidities and cost-associated with IP opioid-related 
injuries. 
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Objective 2 
To determine the socio-demographic subgroups and drug injection practices of the IDU 
population within Clark County. 
Objective 3 
To determine if there is a difference in geographical patterns based on income among 
those who use hospitals and those who use SEPs. 
Hypotheses 
 To answer the research question, the following hypotheses will be tested. 
Hypothesis 1 
Ho: Increasing costs will not be positively associated with the total number of 
comorbidities. 
Ha: Increasing costs will be positively associated with the total number of comorbidities. 
Prediction:  The number of comorbidities will be positively correlated with higher costs. 
Hypothesis 2 
Ho: There will be no difference in socio-demographic subgroups of those who use 
hospitals and those who use SEPs. 
Ha: There will be a difference in socio-demographic subgroups of those who use hospitals 
and those who use SEPs. 
Prediction:  There will be a difference in socio-demographic subgroups of those who use 
hospitals and those who use SEPs. 
Hypothesis 3 
Ho: There will be no difference in geographical patterns based on income among those 
who use hospitals and those who use SEPS. 
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Ha: There will be a difference in geographical patterns based on income among those 
who use hospitals and those who use SEPs. 
Prediction: A higher frequency of IDUs will be seen in zip codes of higher need and a 
higher frequency of opioid-related hospitalizations will be seen in zip codes of lower 
need.  
Methods 
This is a cross-sectional, population-based study that used hospitalization data from 
CHIA and IDU data from Trac-B.  CHIA includes patient billing discharge data from all 
hospitals and ambulatory surgical centers licensed to operate in Nevada.  ICD-10-CM diagnoses 
codes that include any variation of opioid abuse or dependency (see Appendix A for ICD-10-CM 
diagnoses codes) were used to measure the frequency of opioid-related hospitalizations from the 
CHIA database, identified as having an appropriate ICD-10-CM diagnosis in one of the primary, 
secondary, or tertiary diagnosis variables.  Client information from Trac-B’s database is self-
reported and all registered participants were considered IDUs.   
Study Sample 
The study sample included 9,064 opioid-related hospitalizations provided by the 2017 
CHIA database and 1,252 clients (IDUs) who registered at Trac-B from February 2017 to 
February 2018.  
Statistical Analysis 
All data were analyzed using IBM SPSS Statistics 24.0 software. The first hypothesis 
was tested by examining total costs as a function of number of comorbid conditions associated 
with opioid-related injuries using a Spearman-rank correlation. In addition, total costs as a 
function of length of stay (LOS) of opioid-related hospitalizations was investigated using 
Spearman-rank correlation.   
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The second hypothesis involved the analysis of frequencies for each demographic 
variable of interest in both CHIA and Trac-B datasets using contingency tables and chi-square 
statistics. The variables assessed from both CHIA and Trac-B, included age, gender, and 
race/ethnicity. In addition, analyses included variables available in Trac-B data only, including 
drugs injected, frequency of injection per day, sharing characteristics, and Naloxone distribution.  
Finally, for the third hypothesis, a Geographical Information System (GIS; ArcMap 
10.3.1, ESRI) map was generated to indicate the SocioNeeds index of each Clark County zip 
code. This index is calculated nationwide and ranks each zip code within the U.S. from zero to 
100 (Healthy Southern Nevada: SocioNeeds Index, 2018). The SocioNeeds Index (2018) takes 
into account SES factors, such as, poverty level and education and then assigns an index number 
to the zip code area. An index of 100 indicates areas of high need and correlates with high rates 
of preventable hospitalizations and premature death. An index approaching zero, indicates areas 
of low need and low rates of preventable hospitalizations and premature death. An index of 50 
would indicate the national average. This index was used to determine each SocioNeeds rank of 
each zip code within Clark County, as well as, generate maps to indicate the frequency of opioid-
related hospitalizations and injection drug usage within Clark County.  
Ethical Considerations 
This project has been approved by the UNLV Office of Research Integrity for Exempt 
IRB approval for secondary analysis of de-identified data (Appendix C). Additionally, the Data 
Use Agreement between CHIA and the School of Community Health Sciences (SCHS) was 
approved by the State (Nevada Division of Health Care Financing and Policy). 
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Results 
 According to 2017 CHIA data, there was a total of 9,064 opioid-related inpatient cases. 
Of the 9,064 opioid-related cases, 5,268 were Clark County residents. Within Trac-B’s first year 
of opening, 1,252 IDUs became registered clients.  
Cost Analysis & the Number of Comorbidities 
Using 2017 CHIA data, opioid-related hospitalizations were first isolated. Next, 
comorbidities associated with opioid-related injuries were grouped by comorbidity category and 
ranked by frequency (Table 1).  
Table 1. Top 10 Comorbidity Categories Associated with Opioid-Related Hospitalizations 
Rank ICD-10 Codes Comorbidity Categories Frequency 
1 A00-B99 Certain infectious and parasitic diseases* 41356 
2 C00-D49 Neoplasms 15206 
3 F01-F99 Mental, Behavioral and Neurodevelopmental disorders* 11802 
4 E00-E89 Endocrine, nutritional and metabolic diseases 5761 
5 D50-D89 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism 4603 
6 I00-I99 Diseases of the circulatory system 2659 
7 G00-G99 Diseases of the nervous system 2618 
8 S00-T88 Injury, poisoning and certain other consequences of external causes 1288 
9 M00-M99 Diseases of the musculoskeletal system and connective tissue 1129 
10 K00-K95 Diseases of the digestive system 1074 
*Breakdowns of the comorbidity categories: certain infectious and parasitic diseases; and mental, behavioral and neurodevelopmental disorders are in appendix B. 
 
It was determined the categories of highest frequency of comorbidities associated to opioid-
related hospitalizations included: certain infectious and parasitic diseases; neoplasms; mental, 
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behavioral and neurodevelopmental disorders; Endocrine, nutritional and metabolic diseases; and 
diseases of the blood and blood-forming organs and certain disorders involving the immune 
mechanism. 
Cost analysis was conducted by taking “Total Charge” of the comorbidity categories 
listed in Table 1 and the “Total Number of Comorbidities.” It should be noted that data are not 
cost-equalized among participating hospitals in the data. Spearman-rank correlation suggested 
increasing costs was positively associated with the total number of comorbidities listed in Table 
1 (Spearman rho value = 0.046, p <0.0001), but the magnitude of the effect was small. This 
indicates the correlation between “Total Charge” and the “Total Number of Comorbidities” is 
most likely not useful.  
Because there were several ICD-10 codes within each comorbidity category, the top 10 
specific ICD-10 codes associated with opioid-related injuries were identified and ranked by 
frequency (Table 2).   
 
 
Table 2. Top 10 Comorbidity Specific ICD-10 Codes Associated to Opioid-Related Hospitalizations 
Rank ICD-10 Codes Comorbidity Specific Category Frequency 
1 G8929/G894/M549 Chronic Bodily Pains 4549 
2 E785/E876/E871/E860 Malnutrition 4288 
3 F17210/F17200/Z87891 Nicotine Dependence 4050 
4 F419/F329 Affective Disorder 2939 
5 I10 Hypertension 2607 
6 K219 Gastro-Esophageal Reflux Disease 1204 
7 N179 Acute Kidney Failure 983 
8 J449 Chronic Obstructive Pulmonary Disease (COPD) 901 
9 R45851 Suicidal Ideations 900 
10 D649 Anemia 772 
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The ICD-10 codes of highest frequency for comorbidities associated with opioid-related 
hospitalizations included: chronic bodily pains, malnutrition, nicotine dependence, affective 
disorder, and hypertension (Table 2). The specific ICD-10 code comorbidity categories in Table 
2 were different from Table 1; therefore, a repeated cost analysis was performed for Table 2. 
Cost analysis was conducted by taking “Total Charge” and the “Total Number of ICD-10 Codes” 
listed in Table 2. Spearman-rank correlation suggested increasing costs was positively associated 
with the total number of ICD-10 Codes listed in Table 2 (Spearman rho value = 0.036, p 
<0.0001); however, the magnitude of the effect was small. This indicates the correlation between 
“Total Charge” and the “Total Number of ICD-10 Codes” may not be useful. 
Cost Analysis & the Length of Stay  
 To further analyze the “Total Charge”, analysis of the “LOS” from the comorbidity 
categories listed in Table 1 indicated there was no correlation (Spearman rho = 0.008, p = 0.46); 
however, this value was not statistically significant. This process was repeated using the ICD-10 
codes listed in Table 2, which showed a positive correlation between “LOS” and “Total Charge” 
for specific ICD-10 codes (Spearman rho = 0.378, p < 0.0001). The Spearman rank value 
indicates there is a positive correlation between “Total Charge” and “LOS” when analyzing 
specific ICD-10 codes (Table 2).  
Socio-demographic Subgroups 
Age Groups – Cross tabulations among each age group between CHIA hospitalizations 
and Trac-B clients indicated there was no significant difference in the proportion of those 17 
years or younger (Table 3).  
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Table 3. CHIA 2017 IP & Trac-B 2017 IDU Population Demographics* 
Characteristics CHIA n (%) 
Trac-B 
n (%) Test Statistic Significance 
Age (years) n = 9064 n = 1252   
≤ 17 90 (1.0) 16 (1.3)   
18-35 2937 (32.4) 586 (46.8)  CHIA < Trac-B 
36-64 4488 (49.5) 446 (35.6) x2 = 122.3 CHIA > Trac-B 
≥ 65 1549 (17.1) 169 (13.5) p < .001 CHIA > Trac-B 
No Response -- 35 (2.8)   
Gender     
Female 4575 (50.5) 428 (34.2) z = 32.7 % Female: 
Male 4489 (49.5) 796 (63.6) p < .001 CHIA>Trac-B 
Female to Male -- 1 (0.1)  % Male: 
Male to Female -- 2 (0.2)  CHIA < Trac-B 
No Response -- 25 (2.0)   
Race/Ethnicity     
White/Caucasian 6670 (73.6) 928 (74.1)   
Black/African American 926 (10.2) 22 (1.8) x2= 238.05  
Asian/Pacific Islander 92 (1.0) 13 (1.0) p < .001  
Native American/Alaskan 108 (1.2) 30 (2.4)   
Other 496 (5.5) 186 (14.8)   
No Response -- 73 (5.9)   
Unknown 246 (2.7) --   
Hispanic 526 (5.8) --   
Hispanic/Latino     
Yes  192 (15.3)   
No  908 (72.5)   
No Response  152 (12.2)   
*Trac-B data includes data from February 2017 through February 2018. 
There was a significant difference between CHIA and Trac-B samples among all other age 
groups (x2 = 122.33, p < 0.001). There was a higher proportion of those in the age group 18-35 
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years, who used SEPs as compared to the 18-35 year olds who used hospitals (Table 3). There 
was a higher proportion of those who were 36 years old or older, who used hospitals as 
compared to those in the same age group who used SEPs (Table 3).  
Gender – There appears to be an association between those who use hospitals versus 
SEPs and gender (z = 32.7, p < 0.001) (Table 3). There were significantly more females who 
used hospitals as opposed to females who used SEPs. On the contrary, there were significantly 
more males who used SEPs as opposed to males who used hospitals. 
 Race & Ethnicity – There was a significant difference in the proportion of those who are 
of Black/African American race/ethnicity, who used hospitals as compared to the Black/African 
Americans who used SEPs (Table 3). There was a significant difference in the proportion of 
those who are of Native American/Alaskan race/ethnicity, who used SEPs as compared to Native 
American/Alaskans who used hospitals (Table 3). In addition, the proportion of those who are of 
Other race/ethnicity was significantly different from those who used SEPs as compared to Other 
race/ethnicity who used hospitals (Table 3). There were no significant differences between the 
White/Caucasian race/ethnicity groups among CHIA and Trac-B data. 
Trac-B Injection Demographics 
There was a high percentage of IDUs who reported injecting heroin, followed by 
methamphetamines, and speedball (Table 4).  
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Table 4. First Year Trac-B-Exchange Drug Preference of IDU Population  
Drugs Used* Yes n (%) 
No 
n (%)  
Heroin 889 (71.0) 363 (29.0) 
Methamphetamines 767 (61.3) 485 (38.7) 
Speedball1 342 (27.3) 910 (72.7) 
Cocaine 139 (11.1) 1113 (88.9) 
Opioids 179 (14.3) 1073 (85.7) 
Steroids1 45 (3.6) 1207 (96.4) 
         Hormones1 19 (1.5) 1233 (98.5) 
*Data does not reflect if the Trac-B client marked multiple drugs on one survey. 
1. Speedball is a mixture of heroin and cocaine, steroids and hormones may be injected illegally by the transgender population 
 
 
The majority of IDUs reported injecting four to 10 times per day, followed by  
0-3 times per day, and a low rate of IDUs reported injecting greater than 10 times per day (Table 
5).  
 
 
Table 5. First Year Trac-B-Exchange Injection Patterns of IDU Population  
Injection Times per Day n (%) = 1252 (100) 
0 – 3 times 463 (37.0) 
4 to 10 times 540 (43.1) 
        >10 times 51 (4.1) 
Rarely1 57 (4.6) 
Other Response* 10 (0.8) 
No Response 131 (10.5) 
*Other Response = answers that were difficult to place in an Injection category. 
1.Rarely = may inject 5 times per week or month 
 
Of the IDUs who participated in Trac-B’s program, many reported to have shared drugs, have 
shared injection equipment, and have shared needles (Table 6).  
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Table 6. First Year Trac-B-Exchange Sharing Characteristics of IDU Population 
Sharing Characteristics 
n = 1252 
Yes 
n (%) 
I have in the past 
n (%) 
No 
n (%) 
No Response 
n (%) 
         Share Drugs 671 (53.6) -- 540 (43.1) 41 (3.3) 
Sharing Equipment 332 (26.4) -- 853 (68.1) 67 (5.4) 
Sharing Needles 162 (12.9) 4 (0.4) 1038 (82.9) 48 (3.8) 
 
 
Trac-B data indicated 421 Narcan/Naloxone kits were distributed; however, this includes 
initial kits and refills. The data reflects clients who may have received multiple kits within the 
past year. Most of the Narcan/Naloxone kits were given to those who were between the ages of 
18 to 34 years (Table 7).  
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Table 7. Trac-B-Exchange Naloxone Kit Distribution by Age & Gender of IDU Population 
Characteristic Mean Age 
Median 
Age 
Mode 
Age 
(Min, Max) 
Age 
 
n (%) 
 
Age (years) 34.93 33.00 27.00 (11, 67) n=421 (100) 
≤ 17     1 (0.2) 
18-34     229 (54.4) 
35-52     135 (32.1) 
53-71     40 (9.5) 
72-88     0 (0.0) 
No Response     16 (3.8) 
Gender      
Female     136 (32.3) 
Male     194 (46.1) 
Female to Male     0 (0.0) 
Male to Female     2 (0.5) 
Other     1 (0.2) 
No Response     88 (20.9) 
 
 
Males were more likely to request Narcan/Naloxone kits compared to other gender groups. 
Geographical Patterns Based on Income 
The SocioNeeds Index ranks each zip code within the U.S. from 0-100; however, for this 
study it was modified to five ranks for simplicity (1 = area of low need, 5 = area of high need) 
(Figure 1). 
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Figure 1. Clark County zip codes by SocioNeeds Index 
 
 
 
Many zip codes within the center of Clark County (red regions) are areas of high need, which 
indicates a high rate of poor health outcomes. As the map branches out from the center of Clark 
County, more urban areas are designated by the color green, indicating areas of low need or low 
rates of poor health outcomes (Figure 1).  
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Homelessness 
The SocioNeeds Index does not include those who may be transient or of homeless 
status. CHIA data do not provide this information directly; however, CHIA data do provide a 
code, Payer 23, which indicates County Indigent Referral. Those who claim Payer 23 are unable 
to pay for their hospital care and may have alternative ways to pay for their medical expenses or 
they may be transient. In 2017, 169 (1.86%) opioid-related cases reported Payer 23, which likely 
captures the transient population in the database.  
Trac-B’s data directly provides homelessness status because of the required registration 
forms that are mandatory before equipment are dispersed. Based on self-reported data, 378 
(30.2%) of Trac-B’s clientele reported homelessness status.   
Cases by Zip Code 
 Using Clark County zip code maps, frequencies of CHIA opioid-related cases were color-
coded within each zip code (Figure 2).  
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Figure 2. Clark County Frequency of Opioid-Related Cases by Zip Code.  
 
The zip codes that are red, indicate where opioid-related injuries were highest for 2017. 
The red area near the letter A, is zip code 89108, which is known for section 8 housing and 
borders an area known for high crime. The red areas near letters B and C, indicate zip codes 
close to medical facilities (B – Spring Valley Hospital; C – UMC Hospital). The majority of the 
red areas on Figure 2, associate with a high SocioNeeds index.   
Trac-B clientele revealed only two zip codes with a high frequency of injection drug use 
(Figure 3).  
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Figure 3. Clark County Frequency of Intravenous Drug Users by Zip Code 
 
The red area near A (Figure 3) is zip code 89108 and is a common zip code for a high 
frequency of opioid-related hospitalizations seen in Figure 2. The red area near D (Figure 3) is 
the zip code 89107 and borders the street that Trac-B’s storefront is located. Because 30.2% of 
Trac-B’s clientele reported homelessness, we can expect the majority of clients to travel by foot 
or bike because of their close residence to Trac-B. There were no other shared zip codes in terms 
of high frequencies for hospitalizations and injection drug use.  
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There were six total zip codes within Clark County to have a high frequency of opioid-
related hospitalizations and two zip codes within Clark County to have a high frequency of 
injection drug use. The zip code 89108, demonstrated both a high frequency of opioid-related 
hospitalizations and injection drug use; in addition, it is an area of high need according to the 
SocioNeeds Index (Figure 1).  
Discussion 
In 2017, there were 9,064 opioid-related hospitalizations (ORH) in Nevada State, of these 
5,268 occurred within Clark County. This is an increase compared to Feng et al.’s (2016) Clark 
County study, where they found 5,016 ORHs within a 3-year time frame from 2011-2013. This 
increase in ORHs could be the result of Nevada’s high prescription rate, contributing to the 
opioid epidemic, or a result of differences in codes used for data extraction under ICD-10 as 
discussed below.  
This study revealed that 58% (n=5,268) of ORH’s occurred in Clark County in 2017, 
which is surprisingly low considering 75% of Nevada residents live in Clark County (U.S. 
Census Bureau, 2018a). The remainder 42% of ORHs that occurred in 2017 happened in less 
populated areas of Nevada. Aside from Clark County (population = 2.2 million) (U.S. Census 
Bureau, 2018b) and Washoe County (population = 460,587) (U.S. Census Bureau, 2018c), all 
other counties within Nevada do not exceed a population of 54,745 residents, with Esmeralda 
County having the lowest population of 850 residents (U.S. Census Bureau, 2018d). This may be 
evidence that many of the ORHs could be occurring in more rural areas of Nevada or medical 
facilities within these areas are capturing more ORHs.  
Comorbidities Associated to Opioid-Related Hospitalizations 
When investigating comorbidities associated with ORHs, many of the comorbidities with 
high frequencies were consistent with Feng et al.’s (2016) study; such as: chronic bodily pains, 
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affective disorders, hypertension, renal failure, and chronic lower respiratory disease. When 
looking at the number of cases for chronic bodily pains, Feng et al. (2016) found 2,253 cases 
between 2011 and 2013; however, for 2017 there were 4,549 ORHs associated with chronic 
bodily pains. According to the Nevada Division of Public and Behavioral Health (2017), opioid-
related hospitalizations have increased substantially since 2011 in both emergency department 
(ED) visits and hospitalizations; however, there may be another explanation that may account for 
this increase.  
Moore and Barrett (2017) found within the first quarter of ICD-10-CM implementation, 
ORIs increased by 18.3%. Previously, under the ICD-9-CM coding system there were 20 opioid-
related codes; however, under the ICD-10-CM coding system ORI’s became more specified, 
increasing from 20 to 100 opioid-related codes. This modification allowed medical facilities to 
accurately diagnose ORI’s compared to previous years using ICD-9-CM codes. Feng et al.’s 
(2016) study investigated CHIA data from 2011 to 2013; however, ICD-10-CM implementation 
began October 2015. It is possible that ORIs may not have been accurately diagnosed leading to 
a misrepresentation of the number of ORIs within the timeframe of their study. This project 
analyzed CHIA data from 2017 that implemented ICD-10-CM codes providing an updated 
analysis of ORHs within Nevada and Clark County. Having an accurate analysis of ORHs will 
allow Nevada public health officials to observe trends of opioid abuse and will aid in appropriate 
opioid-related interventions.  
Cost Analysis 
 When analyzing the number of comorbidities and cost, unexpectedly there were no 
meaningful correlations observed. It is possible a single comorbidity may have a higher cost 
compared to a patient who had three comorbidities of lower value; alternatively, after examining 
LOS associated with cost, a potential story emerged. Using the ICD-10-CM codes listed in Table 
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2, a positive correlation between LOS and cost was observed; therefore, longer hospital stays 
accrue higher costs.  
 In addition, the mean cost evaluated for ORHs for 2017 (n=9,064) was estimated to be 
$72,632 with the mean LOS of approximately 7 days. Looking at all hospitalizations for 2017 
(n=352,262), the mean cost was $74,975 with the mean LOS of 5.27 days. When comparing 
ORHs to all hospitalizations for 2017, the LOS was higher for ORHs. Considering that LOS is 
positively associated with higher cost, we can expect those hospitalized for an ORI may be 
accruing higher hospital costs as a function of longer stays. On the contrary, the mean cost was 
estimated to be lower for ORHs when compared to all hospitalizations; however, it was not 
meaningfully different from the mean cost of all hospitalizations. Further, costs are not 
universally standardized across procedures at different hospitals, which could confound the 
comparisons. 
Trac-B Analysis 
Analysis of Trac-B’s first year of clientele, revealed that 71% of IDUs inject heroin and 
the average IDU injects 4-10 times per day. In addition, sharing characteristics revealed IDUs are 
sharing equipment and syringes; however, there was a higher percentage of those that reported 
sharing drugs. The question of whether an IDU shares drugs may have several interpretations. 
For instance, are IDUs simply giving a dose to their friend before it is cooked? Or are two IDUs 
putting both of their syringes into the same cooker and taking in their dose? Because 53.6% 
reported sharing drugs, it is possible that they are also sharing equipment, resulting in the 
potential for infectious disease transmission. Because these questions are based on self-reported 
surveys, the interpretation of this question by IDUs may be unclear; therefore, revealing areas of 
improvement within Trac-B’s surveys. In addition, this analysis provides valuable information 
for the purposes of research and the services offered in their facility.   
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For 2017, Trac-B had successfully distributed 206,140 sterile syringes; disposed of 
105,136 used syringes; and administered 130 HIV and 101 HCV tests. Of these tests, three 
(2.3%) positive HIV and 32 (31.7%) positive HCV tests were confirmed. Clients who tested 
positive were contacted by a representative from the Southern Nevada Health District and 
referred for treatment. The current AIDS foundation in Clark County, Aid for AIDS of Nevada 
(AFAN) reported administering 100 HIV tests for the year 2017 and found that two of these tests 
were positive (AFAN representative, personal communication, October 2018). AFAN is not 
specific about who they test; however, Trac-B’s target population is of a high-risk group known 
for high rates of HIV/HCV transmission. This emphasizes the importance of Trac-B’s services 
within the community.  
Of the 206,000 sterile syringes distributed, 14,000 were dispersed through Trac-B’s 
vending machines. The average cost of a single syringe is approximately $0.08 and each syringe 
is equivalent to one prevented HIV infected person, which may cost up to $379,668 for a single 
lifetime of HIV treatment (Aldrich, 1993; CDC, 2017a). Trac-B’s innovative method of 
distributing syringe kits through vending machines is not only cost-effective, but allows more 
IDUs to access sterile injection equipment. By identifying zip codes with high frequencies for 
both ORHs and IDUs, Trac-B can strategically place future vending machines in these locations, 
increasing access to sterile injection equipment; therefore, preventing the transmission of 
HIV/HCV. In addition, Trac-B offers an array of services to IDUs, proving to be a public health 
asset to the state of Nevada by filling in the gap between a high-risk population in need and 
access to health care.  
Currently, Trac-B is grant funded and most SEPs in the U.S. are not federally funded 
(Jarlais, McKnight, & Milliken, 2004). Many are funded through foundation grants and/or 
private donations (Jarlais, McKnight, & Milliken, 2004). SEPs are experiencing a financial crisis 
26 
 
due to the ban on federal funding, in addition HIV prevention funds have been reallocated away 
from IDU transmission (Guardino, Des Jarlais, Nugent & Purchase, 2014). This federal ban was 
one of the contributing factors for the 2015 HIV outbreak that occurred in Scott County, Indiana 
(Rich & Adashi, 2015). There were approximately 153 confirmed HIV cases that were the result 
of syringe sharing in this low-income community (Rich & Adashi, 2015). Many researchers 
suggest this preventable incident will happen again, as long as SEPs remain illegal in many states 
(Rich & Adashi, 2015). In fact, SEPs have been controversial since the wake of their 
development during the HIV pandemic in the 1980’s.  
The controversy behind the legalization of SEPs was argued by many public officials 
believing SEPs would promote and exacerbate the injection of drugs, as well as increase the 
incidence of HIV cases (Rich & Adashi, 2015). However, decades of research investigations 
demonstrate that SEPs are safe and effective at reducing disease transmission and promoting 
referral to treatment facilities (Rich & Adashi, 2015). One study found that SEPs had increased 
in quantity from 60 SEPs within the U.S. in 1994 to approximately 127 in 2000 (Jarlais, 
McKnight, & Milliken, 2004), indicating the increased acceptance of SEPs within communities 
and the role they play in HIV prevention. However, as previously mentioned many states refuse 
to legalize SEPs, despite decades of research demonstrating SEP effectiveness.  
The cost-efficiency of SEPs (less than $100,000 annually) versus the overall opioid 
epidemic cost burden of 504 billion dollars is incomparable (HHS, 2017b). The first-year 
analysis of Trac-B’s data has proven to be an effective intervention on combating the public 
health concerns resulting from the current opioid epidemic. Given the information derived from 
this study, it is evident that SEPs provide one potential solution or a gateway to addressing many 
public health concerns resulting from the opioid epidemic. 
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Socio-Demographic Subgroups 
Analysis of the socio-demographic subgroups demonstrated that a higher proportion of 
18-35 year olds used SEPs as compared to 18-35 year olds who were admitted into hospitals for 
ORIs. In addition, there was a higher proportion of males registered as clients at Trac-B as 
opposed to the proportion of males who were hospitalized for ORIs. This is consistent with the 
literature showing that most IDUs are men of younger age groups (Cicero et al., 2014). On the 
other hand, there was a higher proportion of those 36 years of age or older who were admitted 
for ORH compared to those in the same age group who used Trac-B’s services, a similarity seen 
in Feng et al.’s (2016) study. By having a younger age group use Trac-B for its services, there 
may be an associated reduction in future hospitalizations when these 18-35 year olds reach the 
older age groups of 36 years and above.  
In addition, there was a higher proportion of females who were admitted in 2017 for 
ORIs compared to females who registered as clients at Trac-B providing a consistent trend of 
what was seen in Feng et al.’s (2016) study. A higher proportion of ORHs were among females, 
aged 55 years and older. These results demonstrate that gender specific interventions are 
necessary to battle prescription opioid abuse as well as injection drug abuse.  
SocioNeeds Index 
Density maps identified zip code 89108 as having high rates for both ORHs and IDUs for 
2017. In addition, the SocioNeeds index map determined that 89108 is an area of high need or 
low-SES. This implies zip code 89108 as being an area of high priority for intervention regarding 
the adverse outcomes of the opioid epidemic. All factors associated to low-SES may be 
contributing factors to the high rates of ORHs and intravenous drug use. Currently, 89108 has a 
population of 76,236 residents (Healthy Southern Nevada, 2018), is known to have section-eight 
housing, and borders a North Las Vegas community known for high crime rates. In 2017, 247 
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ORHs and 96 IDUs reported this area as their zip code of residence. It is evident that 
interventions need to be targeted in this area, specifically addressing the contributing factors of 
prescription opioid abuse and the injection of illicit opioids in low-SES communities. 
CHIA zip code areas 
 Five out of the six zip codes that demonstrated a high frequency for ORHs were areas 
with a high SocioNeeds Index. The sixth zip code (Figure 2 – red area above the letter B) had a 
SocioNeeds Index that was average to the nation – meaning it’s a typical middle class 
community that demonstrated high rates for ORHs. When combating the effects of the opioid 
epidemic, interventions may not be a one-size fits all solution. Interventions among different 
SocioNeeds Index communities may require tailored programs to address the specific needs of 
the population. In addition, studies identifying what is driving ORHs in this middle-class 
community as opposed to the higher need areas is suggested.   
Trac-B zip code areas 
There were only two zip codes within Clark County to demonstrate high frequencies for 
IDUs: 89108 (previously discussed) and 89107. The zip code 89107 (population = 37,908) is 
located directly below 89108, is an area of high need, and borders the street where Trac-B’s 
storefront is located. Considering 30.2% of Trac-B’s clientele reported homelessness, this could 
explain the close-proximity of IDUs in 89108 and 89107. We would expect many of these clients 
to be walking, riding their bikes, or using another form of transportation associated to close-
proximity to Trac-B. This is an important factor to consider when determining the location of a 
potential SEP storefront location or when distributing new vending machines.  
National Policy on Prescription Opioids  
Currently, the regulation of prescription opioids is the responsibility of the states, 
meaning there are no national laws in the regulation of prescription opioids (CDC, 2018e). 
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However, a CDC funded program called ‘Prevention for States’ was designed to provide state 
funding to battle the ongoing prescription drug overdose epidemic (CDC, 2017c). There are 
currently 29 states receiving CDC funds within the program including Nevada. The strategies of 
‘Prevention for States’ include: maximizing Prescription Drug Monitoring Programs (PDMP), 
community or insurer/health systems interventions, policy evaluations, and rapid response 
projects (CDC, 2017c).  
‘Prevention for States’ is fairly new and not all states are funded. Because there is little 
research on the effectiveness of state regulations regarding the abuse of prescription drugs (CDC, 
2018f), this program may provide the necessary data to determine the impact it has on 
prescription drugs and overdose. In addition, because the regulation of prescription opioids are 
within the responsibility of the states, some states have implemented state-level policies that 
regulate pain clinics and PDMPs, successfully reducing their overdose rate.  
States such as, Florida, New York, Tennessee, Ohio, and Kentucky (CDC, 2017d) have 
established PDMPs, mandating that all providers check the PDMP before prescribing opioids. 
Many of these states have shown reductions in the number of patients seeking multiple providers 
for the same drugs within two years of PDMP establishment. Florida had implemented several 
interventions targeting excessive opioid prescribing from pain clinics in addition to mandating 
PDMPs, resulting in an 80% opioid prescription decrease from 2010 to 2015 (CDC, 2017d). 
Within the five-year timeframe, Florida simultaneously saw a reduction in prescription opioid 
overdose rates (CDC, 2017d). In 2012, Florida specifically saw greater than 50% of oxycodone 
overdose deaths decrease, which was a direct effect of preventing health care providers from 
dispensing prescription opioids from their offices and having an established PDMP (CDC, 
2017d). According to the CDC (2017d), this is the first substantial decrease in drug overdose 
mortality in the past 10 years (CDC, 2017d). 
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Nevada Policy on Prescription Opioids 
As of January 1, 2018, Nevada implemented the Nevada Prescription Drug Abuse 
Prevention Act (Assembly Bill 474 or AB 474) to curb opioid abuse within the State 
(Gov.nv.gov, 2017). AB 474 mandates additional requirements before administering controlled 
substance prescriptions with the purpose of reducing inappropriate prescribing, and hence, 
preventing addiction (Gov.nv.gov, 2017). Although it does not prevent health care providers 
from dispensing prescription opioids from their offices like Florida, it may encourage clinicians 
to find an alternative form of treatment for patients. It will be interesting to see if and how the 
trends of ORHs have changed during 2018 and within the next five years. If this new policy 
decreases the opioid prescriptions per capita in Nevada, but ORHs continue to increase, this may 
suggest the increased abuse of illicit opioids sold on the black market. In addition, continued 
analysis of Trac-B’s data may also contribute valuable information of changing trends of ORHs.  
This epidemic has led to a chain reaction of public health concerns: addiction, heroin 
usage, injection drug abuse, and HIV/HCV transmission. With Nevada having one of the highest 
rates for opioid prescriptions per capita, it is imperative to understand trends of opioid-related 
hospitalizations and intravenous drug use. Only then can we implement interventions and 
programs to battle the opioid epidemic and the consequent public health effects.  
Limitations 
All research must be presented with appropriate caveats, and the limitations of this 
research are highlighted here. CHIA data were de-identified, and therefore, repeat IP admissions 
may have occurred. Trac-B clientele are not required to show identification upon registration. All 
data received from Trac-B are self-reported, which is susceptible to misclassification bias. 
Respondents may over- or under-report drugs they have used or how many times they inject per 
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day.  In addition, the survey data may not reflect true birth dates, gender, race/ethnicity, or zip 
code.   
The cost analyzed in this project was not weighted by medical facility procedural 
multipliers; therefore, the total charges assessed may not be comparable. In addition, the 
population within each zip code was not adjusted, but presented in counts. This may influence 
the number of ORHs and/or IDUs. A large percentage (30.2%) of IDUs reported homelessness, 
which may skew the zip code data if populations were adjusted. However, less than 1.86% of 
ORHs claimed Payer 23, which may not influence the zip code data if adjustments were 
implemented.    
Trac-B services did not start until February 2017, and hence data analyzed included one 
month in 2018; CHIA data analyzed included only 2017 data. Trac-B did not start distributing 
Naloxone kits until April 2017, and therefore this does not provide a complete year of information 
for Naloxone distribution. Clients who seek vending machine access cards may have more than 
one access card. They may have changed their name and/or birth date to receive another access 
card at a different location, therefore they will be counted as two different clients.  
Conclusion 
This project provides the most recent analysis of data on Nevada’s opioid-related 
hospitalizations, as well as, a first-time analysis of Clark County’s IDU population. This analysis 
supplements current research and may serve as a baseline for future research to be done. Only a 
few states have implemented prescribing interventions that have demonstrated a decline in the 
number of patients seeking multiple providers for the same drugs. Florida is the only state to 
have demonstrated substantial reductions in prescription opioid overdose rates. Considering each 
state may have demographic differences of those who abuse prescription and illicit opioids, it 
will be interesting to see if AB 474 influences ORHs and IDUs in Nevada. This project provides 
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information to support harm reduction programs like Trac-B and will hopefully open funding 
opportunities for Trac-B to continue their services within Clark County.  
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Appendix A 
ICD-10 CM Codes for Opioid Related Disorders 
1. ICD-10-CM Codes 
2. F01-F99 Mental, Behavioral and Neurodevelopmental disorders 
3. F10-F19 Mental and behavioral disorders due to psychoactive substance use 
 
Opioid related disorders F11 
Clinical Information  
• Disorders related to resulting from abuse or mis-use of opioids. 
 
Codes 
F11   Opioid related disorders 
F11.1   Opioid abuse 
F11.10  uncomplicated 
F11.11  in remission 
F11.12  Opioid abuse with intoxication 
F11.120 uncomplicated 
F11.121 delirium 
F11.122 with perceptual disturbance 
F11.129 unspecified 
F11.14  with opioid-induced mood disorder 
F11.15  Opioid abuse with opioid-induced psychotic disorder 
F11.150 with delusions 
F11.151 with hallucinations 
F11.159 unspecified 
F11.18  Opioid abuse with other opioid-induced disorder 
F11.181  Opioid abuse with opioid-induced sexual dysfunction 
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F11.182  Opioid abuse with opioid-induced sleep disorder 
F11.188  Opioid abuse with other opioid-induced disorder 
F11.19  with unspecified opioid-induced disorder 
F11.2   Opioid dependence 
F11.20  uncomplicated 
F11.21  in remission 
F11.22  Opioid dependence with intoxication 
F11.220 uncomplicated 
F11.221 delirium 
F11.222 with perceptual disturbance 
F11.229 unspecified 
F11.23  with withdrawal 
F11.24  with opioid-induced mood disorder 
F11.25  Opioid dependence with opioid-induced psychotic disorder 
F11.250 with delusions 
F11.251 with hallucinations 
F11.259 unspecified 
F11.28  Opioid dependence with other opioid-induced disorder 
F11.281  Opioid dependence with opioid-induced sexual dysfunction 
F11.282  Opioid dependence with opioid-induced sleep disorder 
F11.288  Opioid dependence with other opioid-induced disorder 
F11.29  with unspecified opioid-induced disorder 
F11.9   Opioid use, unspecified 
F11.90  uncomplicated 
F11.92  Opioid use, unspecified with intoxication 
F11.920 uncomplicated 
F11.921 delirium 
F11.922 with perceptual disturbance 
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F11.929 unspecified 
F11.93  with withdrawal 
F11.94  with opioid-induced mood disorder 
F11.95  Opioid use, unspecified with opioid-induced psychotic disorder 
F11.950 with delusions 
F11.951 with hallucinations 
F11.959 unspecified 
F11.98  Opioid use, unspecified with other specified opioid-induced disorder 
F11.981  Opioid use, unspecified with opioid-induced sexual dysfunction 
F11.982  Opioid use, unspecified with opioid-induced sleep disorder 
F11.988  Opioid use, unspecified with other opioid-induced disorder 
F11.99  with unspecified opioid-induced disorder 
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Appendix B 
Specified Diagnoses for Selected Comorbidity Categories 
 
Table 8. Specified Diagnoses of Certain Infectious & Parasitic Diseases 
Certain infectious and parasitic diseases A00-B99 Frequency 
Bacterial Diseases 10880 
Intestinal infectious diseases 7190 
Mycoses 4814 
STI's 4807 
Viral infections characterized by skin and mucous membrane 
lesions 3500 
Bacterial and viral infectious agents 3247 
Viral hepatitis 1931 
Other Spirochetal Diseases 1486 
Pediculosis, acariasis and other infestations 971 
Other viral diseases 910 
Tuberculosis 499 
Arthropod-Borne Viral Fevers and Viral Hemorrhagic Fevers 286 
Other infectious diseases 278 
HIV 232 
Protozoal diseases 167 
Sequelae of infectious and parasitic diseases 158 
Total 41356 
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Table 9. Specified Diagnoses of Mental, Behavioral and Neurodevelopmental disorders 
Mental, Behavioral and Neurodevelopmental disorders F01-F99 Frequency 
Mental and behavioral disorders due to psychoactive substance use n = 3107 
         Opioid related disorders 646 
         Alcohol related disorders 522 
         Other stimulant related disorders 438 
         Sedative, hypnotic, or anxiolytic related disorders 340 
         Cannabis related disorders 290 
         Other psychoactive substance related disorders 289 
         Cocaine related disorders 270 
         Nicotine dependence 153 
         Hallucinogen related disorders 125 
         Inhalant related disorders 34 
         Total 3107* 
Mood [affective] disorders 658 
Anxiety, dissociative, stress-related, somatoform and other 
nonpsychotic mental disorders 487 
Mental disorders due to known physiological conditions 356 
Behavioral syndromes associated with physiological disturbances 
and physical factors 224 
Disorders of adult personality and behavior 210 
Behavioral and emotional disorders with onset usually occurring in 
childhood and adolescence 208 
Schizophrenia, schizotypal, delusional, and other non-mood 
psychotic disorders 198 
Pervasive and specific developmental disorders 112 
Intellectual disabilities 28 
Total 5588 
*The total 3107 mental and behavioral disorders due to psychoactive substance use is included in the total 5588 mental, behavioral  
and neurodevelopmental disorders. 
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Appendix C  
Internal Review Board Exclusion 
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